Profile picture

Professor Ingo Hilgendorf

Charité - University Medicine Berlin, Berlin (Germany)
Membership: FESC Member
Follow
Biography
Professor Hilgendorf is clinical director of the Department of Cardiology, Angiology and Intensive Care Medicine, German Heart Center Charité in Berlin. He works as an interventional cardiologist and engages in translational studies and clinical trials in the field of lipid therapy, heart failure, immunomodulation, and coronary and structural heart disease. Following his postdoctoral training at the MGH Center for Systems Biology, Boston, MA, USA, he established his own research group in Freiburg, Germany, studying the role of the innate and adaptive immune system in cardiovascular disease and the impact of traditional and non-traditional risk factors, before taking on his new role in Berlin.
Logo ESC

Contributor content

Repair of the infarcted heart: cellular effectors, molecular mechanisms and therapeutic opportunities
Presentation
Repair of the infarcted heart: cellular effectors, molecular mechanisms and therapeutic opportunities
DNMT3A CHIP-driver mutations ignite the bone marrow
Presentation
DNMT3A CHIP-driver mutations ignite the bone marrow
The physician`s perspective: what prevents us from keeping LDL-C lower for longer? Who are the patients that need more help?
Presentation
The physician`s perspective: what prevents us from keeping LDL-C lower for longer? Who are the patients that need more help?
NLRP3 mediates atheromatous plaque macrophage proliferation
Presentation
NLRP3 mediates atheromatous plaque macrophage proliferation
Incorporating Lp(a) into risk classification for patients with ASCVD.
Presentation
Incorporating Lp(a) into risk classification for patients with ASCVD.
Lipid im- and exporters differentially determine macrophage turnover in the plaque
Presentation
Lipid im- and exporters differentially determine macrophage turnover in the plaque
SYK inhibitor fostamtinib protects from early but not established atherosclerosis when local macrophage proliferation dominates lesion turnover
Presentation
SYK inhibitor fostamtinib protects from early but not established atherosclerosis when local macrophage proliferation dominates lesion turnover

ESC 365 is supported by